@marklewismd @NEJM @MSKCancerCenter Same can be said for msi+. Tumor agnostic approval does not equal a guarantee of response. With msi some tumor types don’t respond… and in fact high tmb msi+ pts drive the response https://t.co/PNNUc8nlyF https://t.co/
. @AaronGoodman33 can tell you all about other microsatellite stable tumors with high TMB or you can read about it in his paper https://t.co/vcnmpHTjBf
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy - CAncer Immunology Research, Goodma…
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy - CAncer Immunology Research, Goodma…
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy - CAncer Immunology Research, Goodma…
Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy - CAncer Immunology Research, Goodman, KurzrockLab https://t.co/IBKDjdSLlU
Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy - PubMed https://t.co/IBKDjdSLlU
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy | Cancer Immunology Research. Good…
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy | Cancer Immunology Research. Good…
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy | Cancer Immunology Research. Good…
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy | Cancer Immunology Research. Good…
Knowing tTMB status is becoming increasingly important in addition to MSI status for determining candidates that may benefit from ICTs. Wonderful Sunday morning read!
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy | Cancer Immunology Research. Good…
Checking MSI is not enough. Need to also know the tumors TMB status.
excellent work Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy | Cancer Immunology Research. Good…
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy | Cancer Immunology Research. Good…
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy | Cancer Immunology Research. Good…
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy | Cancer Immunology Research. Good…
Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy | Cancer Immunology Research. Goodman strikes again https://t.co/ZfmZR8CdRY
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy | Cancer Immunology Research: Goodm…
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy | Cancer Immunology Research: Goodm…
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy | Cancer Immunology Research: Goodm…
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy | Cancer Immunology Research: Goodm…
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy | Cancer Immunology Research: Goodm…
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy | Cancer Immunology Research: Goodm…
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy | Cancer Immunology Research: Goodm…
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy | Cancer Immunology Research: Goodm…
Tumours with high mutational burden show responsiveness to checkpoint blockade expanding the clinical utility.... https://t.co/NS2ZuQkGNW
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy | Cancer Immunology Research: Goodm…
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy | Cancer Immunology Research: Goodm…
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy | Cancer Immunology Research: Goodm…
@alanlparker
RT @aranglezalba: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy | Cancer Immunology Research https://…
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy | Cancer Immunology Research: Goodm…
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy | Cancer Immunology Research: Goodm…
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy | Cancer Immunology Research: Goodm…
RT @aranglezalba: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy | Cancer Immunology Research https://…
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy | Cancer Immunology Research: Goodm…
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy | Cancer Immunology Research: Goodm…
Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy | Cancer Immunology Research https://t.co/7dsrT6uNvw
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy | Cancer Immunology Research: Goodm…
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy | Cancer Immunology Research: Goodm…
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy | Cancer Immunology Research: Goodm…
Key is TMB biomarker to identify IO responsive MSS subgroup.
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy | Cancer Immunology Research: Goodm…
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy | Cancer Immunology Research: Goodm…
Desperately needed biomarker to guide IO response in MSS CRC. One step at the time !
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy | Cancer Immunology Research: Goodm…
Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy | Cancer Immunology Research: Goodman https://t.co/ZfmZR8CdRY
Some great questions re the #TAPUR study and results for #MSS #CRCSM raised by @SassyCell Might you have insights to share @rschilsky ? Thank you. @manjuggm https://t.co/LfnWc3gVDj
RT @rschilsky: We will be looking at this in our #TAPUR data as well! Microsatellite-Stable Tumors with High Mutational Burden Benefit from…
I'm mCRC MS-Stable and TMB intermediate, so watching this research carefully. Hoping researchers can give us MS-Stable folks a backdoor into immunotherapy. Bravo to these researchers looking at this very issue!
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy | Cancer Immunology Research: Goodm…
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy | Cancer Immunology Research: Goodm…
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy | Cancer Immunology Research: Goodm…
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy | Cancer Immunology Research: Goodm…
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy | Cancer Immunology Research: Goodm…
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy | Cancer Immunology Research: Goodm…
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy | Cancer Immunology Research: Goodm…
High TMB is a good biomarker but not perfect. Further analysis needed to group mutations that lead to the benefit. My tweet few years ago, it's more than just a better chance of having a neoantigen(s), loss of chromatin suppression mutations etc. contribut
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy | Cancer Immunology Research: Goodm…
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy | Cancer Immunology Research: Goodm…
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy | Cancer Immunology Research: Goodm…
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy | Cancer Immunology Research: Goodm…
RT @rschilsky: We will be looking at this in our #TAPUR data as well! Microsatellite-Stable Tumors with High Mutational Burden Benefit from…
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy | Cancer Immunology Research: Goodm…
RT @rschilsky: We will be looking at this in our #TAPUR data as well! Microsatellite-Stable Tumors with High Mutational Burden Benefit from…
We will be looking at this in our #TAPUR data as well! Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy https://t.co/mOlBIXPysC
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy | Cancer Immunology Research: Goodm…
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy | Cancer Immunology Research: Goodm…
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy | Cancer Immunology Research: Goodm…
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy | Cancer Immunology Research: Goodm…
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy | Cancer Immunology Research: Goodm…
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy | Cancer Immunology Research: Goodm…
Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy | Cancer Immunology Research: Goodman https://t.co/lxTf9srUmd
RT @CIR_AACR: Read about how #MSS tumors with high #TMB respond to #CheckpointBlockade. https://t.co/9HgrUWcQvp #Immune2Cancer #CIM20 http…
RT @CIR_AACR: Read about how #MSS tumors with high #TMB respond to #CheckpointBlockade. https://t.co/9HgrUWcQvp #Immune2Cancer #CIM20 http…
RT @CIR_AACR: Read about how #MSS tumors with high #TMB respond to #CheckpointBlockade. https://t.co/9HgrUWcQvp #Immune2Cancer #CIM20 http…
RT @CIR_AACR: Read about how #MSS tumors with high #TMB respond to #CheckpointBlockade. https://t.co/9HgrUWcQvp #Immune2Cancer #CIM20 http…
Read about how #MSS tumors with high #TMB respond to #CheckpointBlockade. https://t.co/9HgrUWcQvp #Immune2Cancer #CIM20 https://t.co/HeJQPeMG9d
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy | Cancer Immunology Research https:/…
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy. - PubMed - Goodman https://t.co/nx…
Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy | Cancer Immunology Research https://t.co/5t6jqeUxYh https://t.co/sSiVZ0SXyH
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy. - PubMed - Goodman https://t.co/nx…
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy. - PubMed - Goodman https://t.co/nx…
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy. - PubMed - Goodman https://t.co/nx…
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy. - PubMed - Goodman https://t.co/nx…
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy. - PubMed - Goodman https://t.co/nx…
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy. - PubMed - Goodman https://t.co/nx…
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy. - PubMed - Goodman https://t.co/nx…
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy. - PubMed - Goodman https://t.co/nx…
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy. - PubMed - Goodman https://t.co/nx…
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy. - PubMed - Goodman https://t.co/nx…
Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy. - PubMed - Goodman https://t.co/nxI7IoViLh
Read about how #MSS tumors with high #TMB respond to #CheckpointBlockade! @FoundationATC @UCSDnews #immunotherapy https://t.co/jKlsespClV https://t.co/T7iMVpKu3d
RT @Dr_R_Kurzrock: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy | Cancer Immunology Research: Goodm…